Unknown

Dataset Information

0

Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma.


ABSTRACT: The loss of p16 is a signature event in Human Papilloma Virus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) that leads to increased Cyclin Dependent Kinase 4/6 (CDK) signaling. Palbociclib, a CDK4/6 inhibitor, is active for the treatment of a subset of HNSCC. In this study, we analyzed patient response data from a phase I clinical trial of palbociclib in HNSCC and observed an association between prior cisplatin exposure and CDK inhibitor resistance. We studied the effects of palbociclib on cisplatin-sensitive and -resistant HNSCC cell lines. We found that while palbociclib is highly effective against chemo-naive HNSCC cell lines and tumor xenografts, prior cisplatin exposure induces intrinsic resistance to palbociclib in vivo, a relationship that was not observed in vitro. Mechanistically, in the course of provoking a DNA damage-resistance phenotype, cisplatin exposure upregulates both c-Myc and cyclin E, and combination treatment with palbociclib and the c-Myc bromodomain inhibitor JQ1 exerts a synergistic anti-growth effect in cisplatin-resistant cells. These data show the benefit of exploiting the inherent resistance mechanisms of HNSCC to overcome cisplatin- and palbociclib resistance through the use of c-Myc inhibition.

SUBMITTER: Robinson AM 

PROVIDER: S-EPMC6856201 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma.

Robinson Anthony M AM   Rathore Richa R   Redlich Nathan J NJ   Adkins Douglas R DR   VanArsdale Todd T   Van Tine Brian A BA   Michel Loren S LS  

Cell death & disease 20191114 11


The loss of p16 is a signature event in Human Papilloma Virus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) that leads to increased Cyclin Dependent Kinase 4/6 (CDK) signaling. Palbociclib, a CDK4/6 inhibitor, is active for the treatment of a subset of HNSCC. In this study, we analyzed patient response data from a phase I clinical trial of palbociclib in HNSCC and observed an association between prior cisplatin exposure and CDK inhibitor resistance. We studied the effects of palbo  ...[more]

Similar Datasets

| S-EPMC6973261 | biostudies-literature
| S-EPMC3581858 | biostudies-literature
| S-EPMC6827881 | biostudies-literature
| S-EPMC4305034 | biostudies-literature
| S-EPMC6643134 | biostudies-literature
| S-EPMC4662460 | biostudies-literature
| S-EPMC3530794 | biostudies-literature
| S-EPMC4629062 | biostudies-literature
| S-EPMC10541623 | biostudies-literature
| S-EPMC7905686 | biostudies-literature